Biotechnology - Merck & Co

Filter

Current filters:

Merck & Co

Popular Filters

1 to 25 of 36 results

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

28-04-2014

USA-based biotech firm Agenus has entered into a collaboration and license agreement with pharma giant…

AgenusBiotechnologyLicensingMerck & CoOncologyResearch

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Bionomics in $172 million pain treatment deal with US pharma giant

01-08-2013

Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy

09-05-2013

US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Cerecor acquires rights to NR2B receptor antagonist from Merck & Co

22-04-2013

Privately-held US neuroscience biotech firm Cerecor says that it has acquired exclusive, worldwide rights…

BiotechnologyCerecorLicensingMerck & CoMK-0657Neurological

Zymeworks gets second milestone from Merck & Co under Azymetric platform accord

18-04-2013

Privately-held Canadian biotech firm Zymeworks announced the successful achievement of a second research…

Azymetric platformBiotechnologyLicensingMerck & CoPharmaceuticalResearchZymeworks

Cerecor acquires rights to Merck & Co's COMT inhibitors

22-03-2013

US neuroscience biotech company Cerecor has acquired exclusive, worldwide rights to develop, register…

BiotechnologyCerecorLicensingMerck & CoNeurologicalPharmaceutical

Merck & Co in biosimilars deal with Samsung Bioepis

21-02-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into an agreement with South Korea-based Samsung Bioepis…

Biogen IdecBiotechnologyMerck & CoPharmaceuticalProductionResearchSamsung Bioepis

Merck & Co and Gilead highlight new data at international HIV meeting

16-11-2012

US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

ASBMR 2012: Anabolics and post-marketing studies

25-10-2012

This year's American Society for Bone and Mineral Research (ASBMR) conference, held in Minneapolis, Minnesota,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEli LillyMerck & CoodanacatibPharmaceuticalProliaResearchteriparatideUnigene Labs

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

15-10-2012

Amgen (Nasdaq: AMGN), the world's largest biotech firm, has presented data from several Prolia (denosumab)…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMerck & CoodanacatibPharmaceuticalProliaResearchWomen's Health

1 to 25 of 36 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top